Akebia Therapeutics Inc (AKBA) Stock Analysis
Verdict: AVOID
Vafseo growth is overshadowed by legacy product declines and a debt-heavy balance sheet, triggering a technical breakdown to 52-week lows.
Investment score: 38/100
Analysis as of
Is Akebia Therapeutics Inc stock worth reviewing? The TradeMates thesis
AKBA is in a precarious fundamental position. Despite an EPS beat, the revenue miss and subsequent analyst downgrade have broken the technical support. With a $216M debt load and negative margins, the risk of further dilution or insolvency outweighs the current Vafseo growth narrative.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Akebia Therapeutics Inc opportunities and risks
What speaks for AKBA
- Vafseo Commercial Ramp
What speaks against AKBA
- Legacy Product Attrition
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| AKBA | n/a | 1.1x | n/a | 79.5% | -13.5% | 17.1% |
| CYDY | n/a | n/a | n/a | 0.3% | 655.7% | -7.0% |
| RCEL | n/a | 2.7x | n/a | 81.6% | -57.0% | -11.6% |
| MGNX | n/a | 1.6x | n/a | 69.9% | -44.8% | -28.7% |
| PYXS | n/a | 17.9x | n/a | 99.8% | -589.8% | -27.0% |
| ORGO | n/a | 0.5x | n/a | 67.6% | -19.8% | 8.8% |
| Peer median | n/a | 1.6x | n/a | 69.9% | -44.8% | -11.6% |
Frequently asked questions about Akebia Therapeutics Inc (AKBA)
Is AKBA stock a good investment?
The TradeMates model rates Akebia Therapeutics Inc as AVOID with an investment score of 38/100. AKBA is in a precarious fundamental position. Despite an EPS beat, the revenue miss and subsequent analyst downgrade have broken the technical support. With a $216M debt load and negative margins, the risk of further dilution or insolvency outweighs the current Vafseo growth narrative. This is algorithmic model output, not personal investment advice.
Is AKBA stock a buy?
The TradeMates model verdict for AKBA is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.